Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 25, 369–370 (1 April 2007) | doi:10.1038/nbt0407-369
UK parses merits of value-based drug pricing
Abstract
Drug pricing and reimbursement are the subjects of intense debate worldwide. In February the UK's Office of Fair Trading (OFT) threw its rock into the pool, suggesting a move from the current UK system based on profit controls to one based around therapeutic value.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
